Free Intensive Nov 21–22Free 2-day hands-on Vibecoding Intensive on Nov 21–22 at 16:00 MSK (Sat–Sun) · Live Cohort 3 starts Nov 23Join Free →Cohort 3 (Nov 23)

Hassabis's Isomorphic Labs Raises $5 Billion for AI Drug Design

Isomorphic Labs, Demis Hassabis's AI drug discovery startup, has raised $5 billion. Formally it is an Alphabet subsidiary, but in practice it is a spin-off of DeepMind. The funding will go to IsoDDE, the engine the company uses to design drugs, and to advancing AI-created drug candidates through later trial stages and toward the market. From here on, clinical results will matter more than new funding rounds.

AI-processed from TG: @data_secrets (Data Secrets); edited by Hamidun News
Hassabis's Isomorphic Labs Raises $5 Billion for AI Drug Design
Source: TG: @data_secrets (Data Secrets). Collage: Hamidun News.
Listen to article
Article Fact Sheet & Key Figures
ParameterDetails
Primary sourceTG: @data_secrets (Data Secrets) ↗
Editor-in-Chief
Key metric #1The round was backed by Andreessen Horowitz, Greenoaks and Sequoia Capital
Key metric #2The company's mission is "Solve All Disease"
Key metric #3IsoDDE is Isomorphic's proprietary drug design engine

Over the past couple of years, big money in AI has gone mostly to language models and data centers. Now a meaningful share of that flow is turning toward biotech. Isomorphic Labs, Demis Hassabis's startup, has raised $5 billion in investment. For anyone building AI products, it is a useful case study in what AI looks like when embedded in a very expensive, slow-moving industry, and what investors expect from it.

Who Isomorphic Labs is and who invested

Formally, Isomorphic Labs is an Alphabet subsidiary. In practice, it is a spin-off of DeepMind, which Hassabis leads. The company's mission is bold: "Solve All Disease."

The scientific foundation is clear. DeepMind is known for AlphaFold, a system that predicts the three-dimensional structure of proteins. Isomorphic is trying to turn that groundwork into a business: moving from understanding how proteins are built to designing molecules that could become drugs.

The new round includes Andreessen Horowitz, Greenoaks and Sequoia Capital, along with other investors. The original post refers to the round as Series C. The company's valuation is not disclosed in the announcement, so it is too early to judge it.

Where the $5 billion will go

According to Isomorphic itself, the money will fund two areas.

The first is scaling IsoDDE, the company's proprietary drug design engine. It is easiest to picture as a pipeline: the input is a disease and a target protein, and the output is candidate molecules that developers expect will interact with that target. The better the pipeline, the fewer costly lab tests and failed attempts are needed before arriving at a working molecule. In conventional pharma, this stage takes years and costs hundreds of millions of dollars.

The second is advancing drug candidates already shaped with AI through later trial stages and then to market. Here the emphasis shifts. Earlier, AI drug startups mostly sold the promise of speeding up molecule search. Now Isomorphic is talking about candidates that have to travel the full path to patients.

The company's stated goal is to start a new era of biomedical breakthroughs and deliver next-generation medicines to patients.

What this means for the industry, and the limits

For founders and product leads, the takeaway is this: money is flowing both to general-purpose models and to narrow systems built into a specific industry. Biotech offers a hard measure of results: a molecule either passes trials or it doesn't. The value of AI in such projects depends on how well it fits the entire process, from idea to finished product.

There are limits, too.

  • AI speeds up molecule search and design, but clinical trials remain. They take years, and even a well-chosen candidate can fail in humans.
  • The original announcement discloses neither the number of drugs in development, their stages, nor timelines to market. From these details alone, it is impossible to judge how quickly the money will turn into medicines.
  • About IsoDDE, the source only says it is the company's proprietary engine. It contains no data on architecture or metrics.

What can be noted already: AI biotech now has a player with a very large budget and the scientific reputation of DeepMind. Watch the results of clinical stages, since new funding rounds matter less. Those results will show whether AI actually accelerates drug development or only does so in presentations.

Story

Key Questions Answered

Who Isomorphic Labs is and who invested?

Formally, Isomorphic Labs is an Alphabet subsidiary. In practice, it is a spin-off of DeepMind, which Hassabis leads. The company's mission is bold: "Solve All Disease." The scientific foundation is clear. DeepMind is known for AlphaFold, a system that predicts the three-dimensional structure of proteins. Isomorphic is trying to turn that groundwork into a business: moving from understanding how proteins are built to designing molecules that could become drugs.

Where the $5 billion will go?

According to Isomorphic itself, the money will fund two areas. The first is scaling IsoDDE, the company's proprietary drug design engine. It is easiest to picture as a pipeline: the input is a disease and a target protein, and the output is candidate molecules that developers expect will interact with that target. The better the pipeline, the fewer costly lab tests and failed attempts are needed before arriving at a working molecule.

What this means for the industry, and the limits?

For founders and product leads, the takeaway is this: money is flowing both to general-purpose models and to narrow systems built into a specific industry. Biotech offers a hard measure of results: a molecule either passes trials or it doesn't. The value of AI in such projects depends on how well it fits the entire process, from idea to finished product. There are limits, too. AI speeds up molecule search and design, but clinical trials remain. They take years, and even a well-chosen candidate can fail in humans.

ZK
Zhemal Khamidun — CPO at Alpina Digital, product manager of AlpinaGPT. Building AI products since 2019. Hamidun News is a pet project that grew into a production aggregator with 6,000+ readers.
✦ Private AI Builders Community · Vibe Club

Ship AI Faster with Founders, Engineers & Weekly Architecture Reviews

Inside Vibe Club (hamidun.com/club) — weekly live masterminds with Zhemal Khamidun, Tech Radar, full LMS access, and 370+ production Claude Code skills.

Join Vibe Club →Explore Hamidun Academy
What do you think?
Loading comments…